Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs iShares Core S&P 500 ETF (IVV) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade
iShares Core S&P 500 ETFTrade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs iShares Core S&P 500 ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while iShares Core S&P 500 ETF trades at $776.01. Which is the better fit depends on your goals.

BIOIVV
Market Cap
$9.43B
Sector
HealthBroad Market / Factor
52-Week High
$356.25$776.81
52-Week Low
$241.71$634.93
Enterprise Value
$9.18B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

No Aura AI signal available yet.

iShares Core S&P 500 ETF

IVV, tracking the S&P 500, trades at $776.81, up 0.6% with a bullish technical signal from moving averages. The ETF approaches resistance near $779-$784 amid strong institutional interest, including a 24.8% position increase by First Bank & Trust. Recent news highlights record highs and JPMorgan's raised 2026 target to 8,000, driven by AI-fueled earnings growth.

Outlook remains positive with S&P 500 earnings growth up 51.1% year-over-year, but risks include overbought conditions (RSI_6 at 94.32) and potential consolidation. Investor sentiment is greedy, yet weak market breadth and high valuations warrant caution for near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO

About iShares Core S&P 500 ETF

IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.

Read more on IVV